Technical Analysis for ABUS - Arbutus Biopharma Corporation

Grade Last Price % Change Price Change
grade C 3.66 -3.68% -0.14
ABUS closed down 3.68 percent on Monday, August 10, 2020, on 25 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Down
Historical ABUS trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
MACD Bearish Signal Line Cross Bearish -3.68%
20 DMA Support Bullish -3.68%
Wide Bands Range Expansion -3.68%
Gapped Down Weakness -3.68%
Shooting Star Candlestick Bearish -16.25%
Wide Bands Range Expansion -16.25%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Arbutus Biopharma Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics, and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. The company's products for Hepatitis B virus (HBV) comprise TKM-HBV, a RNAi therapeutic in Phase I clinical trial; OCB-030, a cyclophilin inhibitor drug candidate; CYT-003, a TLR9 agonist; capsid assembly inhibitors for use as oral therapeutics; surface antigen secretion inhibitors; STING agonists, a stimulator of interferon genes research program; cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; and cccDNA epigenetic modifiers, a research program to inhibit the formation of new virus and subviral particles from cccDNA. Its products also include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-Ebola, an anti-ebola viral therapeutic in Phase I clinical trial; and TKM-Ebola-Guinea, an anti-ebola RNAi therapeutic in Phase 2 trial. In addition, the company develops TKM-Marburg to treat Marburg infections; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02, a therapeutic targeting transthyretin amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in August 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Biopharmaceutical Infectious Diseases Hepatitis B Hepatocellular Carcinoma Sexually Transmitted Diseases And Infections Zoonoses PLK1 Arbutus Biopharma Hypercholesterolemia Liver Cancer Pharmaceutical Partners Primary Hyperoxaluria Transthyretin Amyloidosis Tropical Diseases

Is ABUS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 9.02
52 Week Low 0.8214
Average Volume 9,898,435
200-Day Moving Average 2.22
50-Day Moving Average 2.60
20-Day Moving Average 3.61
10-Day Moving Average 3.98
Average True Range 0.68
ADX 50.75
+DI 43.07
-DI 15.91
Chandelier Exit (Long, 3 ATRs ) 6.97
Chandelier Exit (Short, 3 ATRs ) 3.76
Upper Bollinger Band 5.75
Lower Bollinger Band 1.46
Percent B (%b) 0.51
BandWidth 118.87
MACD Line 0.44
MACD Signal Line 0.51
MACD Histogram -0.0707
Fundamentals Value
Market Cap 201.4 Million
Num Shares 55 Million
EPS -5.07
Price-to-Earnings (P/E) Ratio -0.72
Price-to-Sales 164.81
Price-to-Book 1.74
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.89
Resistance 3 (R3) 3.89 3.83 3.85
Resistance 2 (R2) 3.83 3.77 3.82 3.83
Resistance 1 (R1) 3.74 3.73 3.71 3.74 3.82
Pivot Point 3.68 3.68 3.66 3.67 3.68
Support 1 (S1) 3.59 3.62 3.56 3.59 3.50
Support 2 (S2) 3.53 3.58 3.52 3.49
Support 3 (S3) 3.44 3.53 3.47
Support 4 (S4) 3.44